Pep IQ
← Pep IQ
Strong and well-cited. Baar et al. 2017 (Cell, PMID 28340339) introduced FoxO4-DRI as a D-retro-inverso peptide that disrupts the FoxO4-p53 interaction senescent cells use to evade apoptosis. In aged mice, FoxO4-DRI selectively eliminated senescent cells in multiple tissues and improved fitness, fur density, and renal function. Subsequent work (Aging journal 2020) showed FoxO4-DRI reduced senescent Leydig cells and improved testosterone secretion in aged mice. The DRI modification (mirror-image D-amino acids in reversed sequence) makes the peptide highly resistant to enzymatic degradation while preserving target binding.
Community protocols vary widely because there is no validated human dose. Conservative protocols use 1 mg SubQ daily, 5-on/2-off, for 2-week courses, repeated 2–3 times per year. Aggressive community protocols extrapolate directly from the mouse mg/kg figure (~25 mg per injection, 3 doses every other day, 75–100 mg per cycle). The mouse-equivalent human dose using proper allometric scaling (BSA factor ~12.3) would be much lower than direct mg/kg conversion suggests. Cost is a major factor — D-amino acid synthesis is expensive, putting full extrapolated protocols at hundreds of pounds per cycle.
No human clinical trials have been conducted. No human pharmacokinetic, dose-finding, or safety data exists. The peptide has never been formally developed beyond the academic preclinical phase. All human use is self-experimental.
Not approved by any regulatory agency. Sold as a research compound. The theoretical concern with senolytics is that selective killing of senescent cells could expose underlying tissue damage that those cells were containing — the long-term consequences of eliminating senescent cells in older humans are unknown. Quercetin + dasatinib (the alternative pharmacological senolytic combination) at least has a Mayo Clinic IPF human trial; FoxO4-DRI does not.
FoxO4-DRI has one of the most elegant mechanisms in the senolytic space — selective induction of apoptosis in senescent cells by disrupting the FoxO4-p53 binding that protects them. Mouse data is genuinely impressive. But the human evidence is zero, the dose is unvalidated, and the safety profile in aged humans is unknown. Pep IQ flags this as one of the highest-uncertainty compounds on the platform: the science is real, the human protocol is best-guess, and the cost is high. Members considering this should accept that they are participating in self-experimentation with no clinical safety net.
FOXO4-DRI belongs to an entirely different category from most peptides in this book. Where BPC-157 heals, SS-31 restores energy, and Epitalon extends telomeres — FOXO4-DRI kills cells. Specifically, it is designed to kill senescent cells — the so-called "zombie cells" that have permanently exited the cell cycle but refuse to die, accumulating with age and secreting a cocktail of inflammatory compounds that drive tissue dysfunction across the body.
The concept of senolytics — compounds that selectively eliminate senescent cells — has become one of the most active areas of longevity research. The scientific logic is compelling: clear the ageing, dysfunctional cells, allow healthy tissue to regenerate, reduce the chronic inflammatory signalling (the "Senescence-Associated Secretory Phenotype" or SASP) that drives cardiovascular disease, neurodegeneration, and metabolic decline.
FOXO4-DRI was developed from research identifying that senescent cells express high levels of FOXO4 protein, which binds to p53 (a major tumour suppressor and apoptosis regulator) inside the nucleus — effectively preventing p53 from doing its job of triggering cell death. FOXO4-DRI mimics the p53-binding domain of FOXO4, competing for that interaction, freeing p53, and directing it to the mitochondria to trigger apoptosis — but selectively in senescent cells where FOXO4 is highly expressed.
The selectivity of FOXO4-DRI is its most critical property — and the most important thing to understand about its risk profile. In senescent cells, FOXO4 is highly expressed and actively sequesters p53 in the nucleus, preventing apoptosis. In normal, non-senescent cells, FOXO4 is expressed at low levels in only a small fraction of cell types. FOXO4-DRI therefore disproportionately affects senescent cells.
An important 2026 finding from Fight Aging: a company called Cleara Biotech was formed to commercialise FOXO4-DRI but has largely pivoted to investigating the underlying FOXO4-p53 interaction rather than the peptide itself. This "development hell" pattern is common in longevity peptides — promising preclinical data that stalls before human trials, often because the bioavailability, delivery challenges, or cost of peptide synthesis make pharmaceutical development impractical.
The animal data for FOXO4-DRI is genuinely impressive — it is among the strongest preclinical evidence for any longevity peptide. The challenge is the complete absence of human data.